Is screening baby boomers for HCV enough? A call to screen for hepatitis C virus in persons from countries of high endemicity

Liver International

Volumn 34, Issue 10, 2014, Pages 1447-1451

  Asselah, Tarik ^a   Perumalswami, Ponni V ^b   Dieterich, Douglas ^b  

^a CENTRE DE RECHERCHE SUR L INFLAMMATION   (France)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT;

ASIA; AUSTRALIA; BABY BOOMER; DEATH CERTIFICATE; EDITORIAL; EGYPT; END STAGE LIVER DISEASE; ENDEMIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PREVALENCE; SCANDINAVIA; SCREENING; UNITED KINGDOM; UNITED STATES; AFRICA; HEPACIVIRUS; ISOLATION AND PURIFICATION; MASS SCREENING; MIDDLE AGED; PROCEDURES;

AFRICA; ASIA; ENDEMIC DISEASES; HEPACIVIRUS; HEPATITIS C; HUMANS; MASS SCREENING; MIDDLE AGED; PREVALENCE;

EID: 84908098494     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12599     Document Type: Editorial

References (27)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-67.
3. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012; 156: 271-8.
4. Marcellin P, Pequignot F, Delarocque-Astagneau E, et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-7.
5. Schinazi R, Halfon P, Marcellin P, Asselah T. HCV direct-acting antiviral agents: the best interferon-free combinations. Liver Int 2014; 34(Suppl. 1): 69-78.
6. Committee on the Prevention and control of Virla Hepatitis Infections. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C Washington, DC, USA: The National Academies Press, 2010.
7. Recommendations for testing, managing, and treating hepatitis C. 2014 Avilable at (http://www.hcvguidelines.org).
8. EASL. EASL clinical practice guidelines: management of hepatitis c virus infection. J Hepatol 2014; 60: 392-420.
9. Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965.MMWR Recomm Rep 2012; 61 (RR-4): 1-32.
10. McGarry LJ, Pawar VS, Panchmatia HR, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 2012; 55: 1344-55.
11. Rein DB, Smith BD, Wittenborn JS, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Inter Med 2012; 156: 263-70.
12. United States Census Bureau. 2010 [cited 2012 November 8 2012] Available at http://www.census.gov/ (accessed 8 November 2012).
13. Perumalswami PV, Factor SH, Kapelusznik L, et al. Hepatitis outreach network: a practical strategy for hepatitis screening with linkage to care in foreign born communities. J Hepatol 2013; 58: 890-7.
14. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterol 2008; 134: 416-23.
15. Asselah T, De Muynck S, Broët P, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol 2012; 56: 527-32.
16. Drucker E, Alcabes PG, Marx PA. The injection century: massive unsterile injections and the emergence of human pathogens. Lancet 2001; 358: 1989-92.
17. Hauri AM, Armstrong GL, Hutin YG. The global burden of disease attributable to contaminated injections given in health care settings. Int J STD AIDS 2004; 15: 7-16.
18. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-91.
19. Miller FD, Abu-Raddad LJ. Evidence of intense ongoing endemic transmission of hepatitis C virus in Egypt. Proc Natl Acad Sci U S A 2010; 107: 14757-62.
20. Mohamoud YA, Mumtaz GR, Riome S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13: 288.
21. EASL. clinical practice guidelines management of chronic hepatitis B. J Hepatol 2012; 50: 227-42.
22. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recommendations and Reports Morbidity and mortality weekly report.Recommendations and reports/centers for disease control 2008; 57 (RR-8): 1-20.
23. Hezode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon Alfa-2a and ribavirin in treatment-naive HCV-genotype 1 or 4 patients: phase 2b COMMAND-1 SVR12 results. Hepatology 2012; 56(Suppl.): 553A.
24. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1878-87.
25. Ruane PJ, Ain D, Meshrekey R, et al. Sofosbuvir plus ribavirin, an interferon-Free Regimen, in the Treatment of Treatment-Naïve and -experienced patients with chronic genotype 4 HCV Infection. EASL 2014; Abstract 1243.
26. Moreno C, Hezode C, Marcellin P, et al. Once-daily simeprevir (TMC435) with peginterferon/ribavirin in treatment-naïve or treatment-experienced chronic HCV genotype-4 infected patients: SVR12 results of a Phase 3 trial (RESTORE Study). EASL 2014; Abstract 1319.
27. Hezode C, Marcellin P, Pol S, et al. Results from the phase 2 PEARL-I study: interferon-free regimens of ABT-450/R + ABT-267 with or without ribavirin in patients with HCV genotype 4 infection. EASL 2014; Abstract O58.